AG
RYTM icon

Algert Global’s Rhythm Pharmaceuticals RYTM Stock Holding History

Algert Global’s Portfolio RYTM Stock Details RYTM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.26M Buy
83,431
+24,918
+43% +$2.25M 0.11% 296
2026
Q1 		$5.09M Sell
58,513
-29,737
-34% -$2.89M 0.08% 437
2025
Q4 		$9.45M Sell
88,250
-52,034
-37% -$5.52M 0.15% 214
2025
Q3 		$14.2M Buy
140,284
+80,065
+133% +$7.43M 0.24% 97
2025
Q2 		$3.81M Sell
60,219
-1,242
-2% -$76K 0.08% 421
2025
Q1 		$3.26M Buy
61,461
+19,910
+48% +$1.1M 0.08% 428
2024
Q4 		$2.33M Sell
41,551
-12,620
-23% -$697K 0.05% 552
2024
Q3 		$2.84M Sell
54,171
-49,961
-48% -$2.39M 0.08% 439
2024
Q2 		$4.28M Buy
104,132
+35,084
+51% +$1.4M 0.14% 220
2024
Q1 		$2.99M Buy
69,048
+40,245
+140% +$1.76M 0.12% 295
2023
Q4 		$1.32M Sell
28,803
-4,610
-14% -$145K 0.05% 541
2023
Q3 		$766K Sell
33,413
-25,680
-43% -$575K 0.04% 626
2023
Q2 		$974K Buy
+59,093
New +$1.07M 0.04% 668
2021
Q1 		– Sell
-12,080
Closed -$359K – 517
2020
Q4 		$359K Buy
+12,080
New +$307K 0.1% 275

Other funds holding RYTM

RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Algert Global's RYTM Position: Q2 2026 in Review

Algert Global increased its Rhythm Pharmaceuticals (RYTM) stake by 43% in Q2 2026, buying an estimated $2.25M and bringing the position to 83,431 shares worth $9.26M. The position accounts for 0.11% of the portfolio, ranked #296.

Algert Global first reported a position in RYTM in Q4 2020 and has held it in 14 quarters since. The position peaked at $14.2M in Q3 2025. 304 funds tracked by Wall St. Rank hold RYTM as of Q2 2026.

  • Algert Global held 83,431 shares of Rhythm Pharmaceuticals worth $9.26M as of Q2 2026.
  • Algert Global bought 24,918 Rhythm Pharmaceuticals shares in Q2 2026, an estimated $2.25M.
  • Rhythm Pharmaceuticals made up 0.11% of Algert Global's portfolio in Q2 2026, its #296 holding.
  • Algert Global first reported a position in Rhythm Pharmaceuticals in Q4 2020 and has held it in 14 quarters since.
  • Algert Global's Rhythm Pharmaceuticals position peaked at $14.2M in Q3 2025.
  • 304 funds tracked by Wall St. Rank held Rhythm Pharmaceuticals as of Q2 2026.

Based on Algert Global's 13F filing for Q2 2026, filed 13 Aug 2026.